Following a thorough safety review, the USFDA and the CDC have jointly lifted the recommended pause on the use of Ad26.COV2.S vaccine in the US. The medical and scientific teams at the FDA and CDC have jointly approved to lift the recommended pause on the use of Ad26.COV2.S vaccine after six cases of thrombosis along with cerebral venous sinuses (CVST) were reported. The team of investigators had assessed the risk of thrombosis in the brain and other body parts along with the risk of thrombocytopenia, known as thrombosis-thrombocytopenia syndrome (TTS).
The healthcare providers (HCPs) were also made aware of the possible rare adverse events enabling the timely recognition and proper management of TTS after the vaccine administration. The decisions that the FDA and CDC have jointly arrived at include: The United States should resume the use of Ad26.COV2.S vaccine. Based on the available…
